Clinical Trial Update: An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

View source ↗

Summary

An observational study of tocilizumab (RoActemra/Actemra) in patients with rheumatoid arthritis, sponsored by Hoffmann-La Roche, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: TERMINATED